Such factors include liver metastasis16, PS16, duration of ADT treatment16, time from prostate cancer diagnosis17, presence of pain17, PSA18,19, LDH16,17, Alb16, ALP17, Hb18, cycles of chemotherapy18, response to prior chemotherapy18, PSA decline after CRPC treatment20,21, age19, GS19, nadir PSA22, and time to nadir PSA (TNPSA)22. This evidence concerns the gene KLK3 and Familial prostate cancer.